Regentis

PRINCETON, NJ and OR AKIVA, Israel – October 23, 2018 – Regentis Biomaterials todayannounced it has expanded the SAGE clinical trial of GelrinC™ for the treatment of articularcartilage damage in the knee to 11 U.S. sites. GelrinC is an investigational device being evaluatedas a treatment to help the body regrow cartilage in the knee.

MINNEAPOLIS, Minn. – Nov. 27, 2018 – Regentis Biomaterials today announced that Twin Cities-based
TRIA Orthopedics is the first in Minnesota to perform a procedure using the GelrinC™ implant to treat
damaged articular cartilage causing knee pain. GelrinC (pronounce “gel-rin-cee”) is an investigational
device being evaluated as a treatment to help the body regrow cartilage in the knee. TRIA is the only site
in Minnesota – and just one of 17 sites nationwide – enrolling patients with knee pain caused by
damaged knee cartilage in the SAGE clinical trial.